Trexquant Investment LP Nektar Therapeutics Transaction History

Trexquant Investment LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$15.77 - $19.03 $564,849 - $681,616	-35,818 Closed	0 $0
Q3 2020 Nov 06, 2020	SELL	$16.59 - $24.79 $384,108 - $573,962	-23,153 Reduced 39.26%	35,818 $594,000
Q2 2020 Aug 07, 2020	SELL	$16.86 - $23.44 $163,204 - $226,899	-9,680 Reduced 14.1%	58,971 $1.37 Million
Q1 2020 May 08, 2020	BUY	$14.47 - $27.96 $589,146 - $1.14 Million	40,715 Added 145.74%	68,651 $1.23 Million
Q4 2019 Feb 12, 2020	BUY	$15.87 - $23.12 $443,344 - $645,880	27,936 New	27,936 $603,000
Q4 2018 Feb 13, 2019	SELL	$30.43 - $56.65 $2.11 Million - $3.93 Million	-69,340 Closed	0 $0
Q3 2018 Nov 09, 2018	SELL	$46.46 - $68.49 $258,828 - $381,557	-5,571 Reduced 7.44%	69,340 $4.23 Million
Q2 2018 Aug 07, 2018	BUY	$46.25 - $104.45 $3.3 Million - $7.46 Million	71,392 Added 2028.76%	74,911 $3.66 Million
Q1 2018 May 03, 2018	BUY	$57.4 - $108.44 $201,990 - $381,600	3,519 New	3,519 $374,000

154

130M

92.7K

4.9K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $112M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.